|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117471 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-23 23:00:31 |
|
注册时间: Date of Registration: |
2026-01-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
羟考酮联合低剂量丙泊酚行清醒镇痛在误吸高风险患者胃镜麻醉的疗效与安全性评估 ——一项回顾性队列研究 |
|
Public title: |
Evaluation of the efficacy and safety of oxycodone combined with low-dose propofol for conscious analgesia in patients at high risk of aspiration during gastroscopy: A retrospective cohort study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
羟考酮联合低剂量丙泊酚行清醒镇痛在误吸高风险患者胃镜麻醉的疗效与安全性评估 ——一项回顾性队列研究 |
|
Scientific title: |
Evaluation of the efficacy and safety of oxycodone combined with low-dose propofol for conscious analgesia in patients at high risk of aspiration during gastroscopy: A retrospective cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郑宁 |
研究负责人: |
常欢 |
|
Applicant: |
Zheng Ning |
Study leader: |
Chang Huan |
|
申请注册联系人电话: Applicant telephone: |
+86 199 6643 7202 |
研究负责人电话: Study leader's telephone: |
+86 159 7318 0730 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
19966437202@163.com |
研究负责人电子邮件: Study leader's E-mail: |
64811362@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市桐梓坡路138号(中南大学湘雅三医院) |
研究负责人通讯地址: |
湖南省长沙市桐梓坡路138号(中南大学湘雅三医院) |
|
Applicant address: |
No. 138 Tongzipo Road, Changsha, Hunan Province (Xiangya Third Hospital of Central South University) |
Study leader's address: |
No. 138 Tongzipo Road, Changsha, Hunan Province (Xiangya Third Hospital of Central South University) |
|
申请注册联系人邮政编码: Applicant postcode: |
410013 |
研究负责人邮政编码: Study leader's postcode: |
410013 |
|
申请人所在单位: |
中南大学湘雅三医院 |
||
|
Applicant's institution: |
The Third Xiangya Hospital, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅三医院 |
||
|
Affiliation of the Leader: |
The Third Xiangya Hospital, Central South University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
快 251067 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅三医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Xiangya Third Hospital, Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-29 00:00:00 |
||
|
伦理委员会联系人: |
刘作良 |
||
|
Contact Name of the ethic committee: |
Liu zuoliang |
||
|
伦理委员会联系地址: |
湖南省长沙市桐梓坡路138号(中南大学湘雅三医院) |
||
|
Contact Address of the ethic committee: |
No. 138 Tongzipo Road, Changsha, Hunan Province (Xiangya Third Hospital of Central South University) |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 8861 8938 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中南大学湘雅三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Xiangya Hospital, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市桐梓坡路138号(中南大学湘雅三医院) |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 138 Tongzipo Road, Changsha, Hunan Province (Xiangya Third Hospital of Central South University) |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖南省自然科学基金青年项目(No.2022JJ40739)、白求恩公益基金(No.ezme2022-025) |
||||||||||||||||||||||
|
Source(s) of funding: |
Hunan Provincial Natural Science Foundation Youth Project (No. 2022JJ40739), Bethune Charity Foundation (No. ezme2022-025) |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
预防性研究 |
||||||||||||||||||||||
|
Study type: |
Prevention |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
历史对照研究 |
||||||||||||||||||||||
|
Study design: |
Historical control |
||||||||||||||||||||||
|
研究目的: |
误吸高风险患者的胃镜麻醉管理是一个极具挑战性的任务。本研究旨在探讨羟考酮联合低剂量丙泊酚清醒镇痛在此类特殊人群麻醉管理中的有效性和安全性,以期为优化内镜麻醉管理提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
The anesthesia management of high-risk patients for aspiration during gastroscopy is an extremely challenging task. This study aims to explore the efficacy and safety of oxycodone combined with low-dose propofol for conscious sedation in the anesthesia management of this special population, in order to provide a basis for optimizing endoscopic anesthesia management. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.存在误吸高风险患者,如消化道出血或梗阻、消化道解剖学改变等; 2.使用羟考酮行清醒镇痛的胃镜检查的患者; 3.年龄 18 至 80 岁; 4.美国麻醉医师协会(American Society of Anesthesiologists, ASA)分级Ⅰ-Ⅲ级; 5.体重指数(body mass index, BMI)介于 18-30 kg/m^2之间。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients at high risk of aspiration, such as those with gastrointestinal haemorrhage or obstruction, or anatomical alterations of the digestive tract; 2. Patients undergoing gastroscopy with conscious sedation using oxycodone; 3. Aged between 18 and 80 years; 4. American Society of Anaesthesiologists (ASA) physical status classification I–III; 5. Body mass index (BMI) between 18 and 30 kg/m2. |
||||||||||||||||||||||
|
排除标准: |
1.病例资料记录不全的患者,缺失关键变量(如患者疼痛评分等); 2.单纯胃镜检查转变为胃镜下治疗或外科手术干预的患者; 3.在研究过程中,患者的改良观察者警觉/镇静等级量表(Modified Observer's Assessment of Alertness/Sedation Scale,MOAA/S)评分<=3 的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with incomplete case records lacking key variables (such as pain scores); 2. Patients whose simple gastroscopy was converted to endoscopic treatment or surgical intervention; 3. Patients with Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) scores ≤3 during the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-25 00:00:00至 To 2026-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-25 00:00:00 至 To 2026-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
(Case Record Form, CRF) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |